Abstract: The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
June 20, 2023
Assignee:
Pfizer Inc.
Inventors:
Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Kathrin Ute Jansen, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
Abstract: This disclosure provides a new vaccine composition and methods for its use. The composition contains an effective amount of each of: an aluminum hydroxide, a mono-phosphoryl lipid (MPL), and a whole glucan particles (WGP) but no an antigen that raises an immune response against a bacterial or fungal infection.
Type:
Grant
Filed:
October 29, 2018
Date of Patent:
June 13, 2023
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA
Inventors:
Brad Spellberg, Travis Nielsen, Brian Luna
Abstract: An enzymatic extraction agent, as well as methods, compositions and kits for detecting Group A Streptococcus in a biological sample, which involve the enzymatic agent, are described.
Type:
Grant
Filed:
October 11, 2019
Date of Patent:
June 13, 2023
Assignee:
Quidel Corporation
Inventors:
Peter Yan-Guo Ren, Stewart Hoelscher, Cristian Alberto, Stephanie Pinedo, Jason McClure, Hyunjin Kim
Abstract: Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.
Type:
Grant
Filed:
April 2, 2021
Date of Patent:
June 13, 2023
Assignee:
Children's Hospital & Research Center at Oakland
Abstract: This disclosure provides microbes engineered to detect virulent and spore states of pathogens and release an appropriate therapeutic response accordingly and compositions and methods of use of the same.
Type:
Grant
Filed:
September 14, 2020
Date of Patent:
May 30, 2023
Assignee:
Lawrence Livermore National Security, LLC
Inventors:
Mimi-Cho Yung, Matthew A. Coleman, Patrik D'haeseleer, Howard Harris, Yongqin Jiao, Kenneth W. Overton, Dan Mcfarland Park, Brent W. Segelke, Sergio E. Wong
Abstract: The present disclosure relates to probiotics and probiotic compositions having modified energy metabolisms (e.g., modifying, metabolizing, or storing energy molecules, e.g., lipids, before the energy molecules are absorbed by a host subject), and thus modulating the absorption of the energy molecules by the host subject. The present disclosure also relates to methods of making such probiotics and probiotic compositions. The present disclosure further relates to methods of regulating (e.g., maintaining or reducing) body weight in a subject (e.g., a subject having a healthy BMI, a subject having an overweight BMI, a subject having an obese BMI), using the probiotics and probiotic compositions disclosed herein.
Type:
Grant
Filed:
August 27, 2020
Date of Patent:
May 2, 2023
Assignee:
University of Pittsburgh—of the Commonwealth System of Higher Education
Inventors:
Abhinav Prakash Acharya, Steven R. Little
Abstract: The present invention provides a modified botulinum neurotoxin A (BoNT/A) L-chain protease that demonstrates enhanced cleaveage of human SNAP-23 (hSNAP-23) relative to unmodified (wild-type) BoNT/A L-chain protease, together with the use thereof for cleaving hSNAP-23.
Abstract: The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid, as well as a method for obtaining polyclonal antibodies useful for detecting NmX in biological fluids such as cerebrospinal fluid, serum and urine.
Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
Type:
Grant
Filed:
April 1, 2021
Date of Patent:
March 28, 2023
Assignees:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, ACTINOBAC BIOMED, INC.
Inventors:
Scott C. Kachlany, Benjamin A. Belinka, Jr.
Abstract: The present invention is directed towards conjugates comprising fragments of the capsular polysaccharide of Type III Group B Streptococcus (GBS). Suitable fragments may be produced synthetically or by depolymerisation of native polysaccharide.
Type:
Grant
Filed:
March 16, 2017
Date of Patent:
March 28, 2023
Assignee:
GSK VACCINES S.R.L.
Inventors:
Roberto Adamo, Francesco Berti, Filippo Carboni, Immaculada Margarit Y Ros
Abstract: The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
March 21, 2023
Assignee:
Leidos, Inc
Inventors:
Stephen A. Chappell, Vincent P. Mauro, John Dresios
Abstract: Provided herein, in some aspects, are tools (e.g., methods, compositions and nucleic acids) for building genetic circuits in Bacteroides and Parabacteroides bacteria, as well as the bacteria containing the genetic circuits.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
February 28, 2023
Assignee:
Massachusetts Institute of Technology
Inventors:
Timothy Kuan-Ta Lu, Mark K. Mimee, Christopher Voigt, Alex C. Tucker
Abstract: The present invention discloses application of a bile acid composite bacterial agent in the preparation of feed additives for mutton sheep. The bile acid composite bacterial agent comprises Parabacteroides distasonis bacterial suspension and bile acid, and the Parabacteroides distasonis bacterial suspension is obtained by cultivation and fermentation of Parabacteroides distasonis LCG-06 with the deposit number CGMCC No. 20820. The bile acid composite bacterial agent of the present invention has natural components and has no toxic and side effects, and can significantly increase the growth rate of mutton sheep and promote nutrition absorption, accelerate the decomposition of in vivo fat of mutton sheep, thereby reducing the body fat percentage of mutton sheep, increasing the slaughter weight and slaughter rate of mutton sheep, increasing the incomes for breeding of mutton sheep. Therefore, it has broad application prospects.
Type:
Grant
Filed:
October 26, 2021
Date of Patent:
February 28, 2023
Assignee:
Shandong Longchang Animal Health Product Co., Ltd.
Inventors:
Xilei Zhang, Aizhi Cao, Qianqian Lou, Limin Ji
Abstract: A vaccine comprising a protein immunogen capable of stimulating a protective immune response against snake venom as well as spider and bee venoms. The DNA encoding the protein is disclosed. The protein can be expressed in both recombinant host cells. The protein is useful as a thermostable, parenteral administration anti venom vaccine protective against envenomation by diverse snake species, spiders and bees.
Abstract: The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
February 7, 2023
Assignees:
Genome and Company, Lactomason Co., Ltd.
Abstract: The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolisation, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.
Type:
Grant
Filed:
June 30, 2020
Date of Patent:
January 17, 2023
Assignee:
IMMODULON THERAPEUTICS LIMITED
Inventors:
Charles Akle, Satvinder Mudan, John Grange
Abstract: The present invention relates to Lactobacillus plantarum NK3 and Bifidobacterium longum NK49, which are novel lactic acid bacteria and, more particularly, to a composition comprising novel lactic acid bacteria useful for prevention and treatment of inflammatory diseases.
Abstract: The present invention relates to a method of preparing a live attenuated vaccine by irradiation and a live attenuated vaccine composition prepared by the same, and more particularly, a method of preparing a live attenuated vaccine by irradiation including irradiating a pathogenic microorganism with a dose of 0.5 to 2 kGy of radiation per single radiation six to fifteen times; and a live attenuated vaccine composition including a pathogenic microorganism attenuated to not be revertant to a wild type by generation of at least one mutation of nucleotide insertion and nucleotide deletion by irradiation.
Type:
Grant
Filed:
January 8, 2019
Date of Patent:
January 3, 2023
Assignee:
Korea Atomic Energy Research Institute
Inventors:
Ho-Seong Seo, Sang-Yong Lim, Jong-Hyun Jung
Abstract: Disclosed herein is a process for producing a postbiotic extract, which includes providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to form a mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract. Use of the postbiotic extract is also disclosed.